MYC and cancer: c-Myc overexpression is frequently observed in solid as well as hematological cancers, including primary effusion lymphoma (PEL), a B cell lymphoma linked to Kaposi’s sarcoma-associated herpesvirus (KSHV), and multiple myeloma (MM), a plasma cells malignancy, although mutations or translocations usually do not occur in these cancers [1,2].